|
gptkbp:instanceOf
|
gptkb:chemical_compound
Cannabis
|
|
gptkbp:affects
|
gptkb:endocannabinoid_system
|
|
gptkbp:approvedBy
|
FDA (for Epidiolex)
|
|
gptkbp:ATCCode
|
gptkb:N02BG10
|
|
gptkbp:boilingPoint
|
180 °C (decomposes)
|
|
gptkbp:canExtract
|
hemp
marijuana
|
|
gptkbp:CASNumber
|
13956-29-1
|
|
gptkbp:chemicalFormula
|
C21H30O2
|
|
gptkbp:compatibleWith
|
gptkb:cancer
anxiety (by FDA)
general pain
|
|
gptkbp:controversy
|
regulatory status
|
|
gptkbp:discoveredBy
|
gptkb:Roger_Adams
|
|
gptkbp:discoveredIn
|
1940
|
|
gptkbp:eliminationHalfLife
|
18–32 hours
|
|
gptkbp:foundIn
|
cannabis plant
|
|
gptkbp:fullName
|
cannabidiol
|
|
gptkbp:hasApprovedDrug
|
gptkb:Epidiolex
|
|
gptkbp:hasNo
|
intoxicating effects
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CBD
|
|
gptkbp:IUPACName
|
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
|
|
gptkbp:legalStatus
|
varies by country
|
|
gptkbp:marketedAs
|
dietary supplement
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:marketGrowth
|
rapidly increasing
|
|
gptkbp:meltingPoint
|
66 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:psychoactive
|
no
|
|
gptkbp:PubChem_CID
|
gptkb:ChEMBL1044
557239
644019
|
|
gptkbp:receptorInteraction
|
gptkb:CB1_receptor_(indirect)
gptkb:CB2_receptor_(indirect)
|
|
gptkbp:relatedTo
|
gptkb:THC
gptkb:CBN
|
|
gptkbp:sells
|
gptkb:oil
capsule
edible
topical
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
drowsiness
dry mouth
changes in appetite
|
|
gptkbp:solubility
|
lipid-soluble
|
|
gptkbp:status
|
gptkb:Schedule_V_(US,_for_Epidiolex)
|
|
gptkbp:studiedBy
|
neuroprotection
anti-anxiety effects
anti-psychotic effects
anti-seizure effects
|
|
gptkbp:UNII
|
19GBJ60SN5
|
|
gptkbp:usedFor
|
pain management
anti-inflammatory
epilepsy treatment
anxiety relief
|
|
gptkbp:bfsParent
|
gptkb:business
|
|
gptkbp:bfsLayer
|
4
|